Oral Paricalcitol in Kidney Transplant Recipients

Summary

This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this medication. The main possible benefits being studied are: * Lower risk for overactive parathyroid glands after kidney transplantation. * Lower risk of low bone density in the spine and hip after kidney transplantation. By dividing patients in the study into a group receiving Zemplar® and a group not receiving Zemplar®, it will be possible to understand the good and bad effects of Zemplar® during the first year after a kidney transplant.

Timeline

Start

2007-01

Primary completion

2011-11

Completion

2011-11

Drugs

Indications